The itolimuzab trial was ostensibly randomized an
Post# of 150907
(Total Views: 672)
Posted On: 08/13/2020 12:09:54 AM
The itolimuzab trial was ostensibly randomized and controlled, but was open label so who really knows.
Insert-tag-herehttps://www.globenewswire.com/news-release/2020/07/13/2060993/0/en/Clinical-Trial-Shows-Itolizumab-Reduces-Mortality-in-Patients-Hospitalized-with-COVID-19.html
Insert-tag-herehttps://www.globenewswire.com/news-release/2020/07/13/2060993/0/en/Clinical-Trial-Shows-Itolizumab-Reduces-Mortality-in-Patients-Hospitalized-with-COVID-19.html
Quote:
Biocon conducted a randomized, controlled, open-label study at four hospitals in India, enrolling a total of 30 hospitalized COVID-19 patients with moderate to severe ARDS. Twenty patients were randomized to receive itolizumab plus best supportive care, while 10 patients received best supportive care alone. The primary endpoint was mortality at one month. As reported by Biocon:
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼